The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Riva, Enrica ^a   Salvini, Filippo ^a   Garlaschi, Maria L ^b   Radaelli, Giovanni ^a   Giovannini, Marcello ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; PNEUMOCOCCUS VACCINE; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; VACCINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILD HEALTH; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; PROSPECTIVE STUDY; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECT; HEALTH SURVEY; IMMUNOLOGY; INFANT; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; SEROTYPING;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84860379054     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-106     Document Type: Article

References (37)

1. World Health Organization (WHO) Pneumococcal vaccines. Wkly Epidemiol Rec 2003, 78:110-119. World Health Organization (WHO).
2. World Health Organization (WHO) Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol Rec 2007, 82:93-104. World Health Organization (WHO).
3. Deloria-Knoll M, O'Brien KL, Henkle E, Lee E, Watt JP, McCall N, Mangtani P. Global literature review of Haemophilus influenzae type b and Streptococcus pneumoniae invasive disease among children less than five years of age, 1980-2005. http://whqlibdoc.who.int/hq/2009/WHO_IVB_09.02_eng.pdf (accessed October 29, 2011)..
4. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, . Hib and Pneumococcal Global Burden of Disease Study Team Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. 10.1016/S0140-6736(09)61204-6, 19748398, Hib and Pneumococcal Global Burden of Disease Study Team.
5. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, . Active Bacterial Core Surveillance of the Emerging Infections Program Network Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746. 10.1056/NEJMoa022823, 12724479, Active Bacterial Core Surveillance of the Emerging Infections Program Network.
6. Centers for Disease Control and Prevention (CDC) Invasive pneumococcal dis ease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57:144-148. Centers for Disease Control and Prevention (CDC).
7. Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, Spanjaard L, Sanders EA, van der Ende A. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16:816-823. 2953990, 20409372.
8. Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Andersen PH, Howitz M, Krogfelt KA, Lambertsen L, Konradsen HB. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28:2642-2647. 10.1016/j.vaccine.2010.01.017, 20096392.
9. Pulido M, Sorvillo F. Declining invasive pneumococcal disease mortality in the United States, 1990-2005. Vaccine 2010, 28:889-892. 10.1016/j.vaccine.2009.10.121, 19879229.
10. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354. 10.1086/521626, 17922399.
11. Hsu KK, Shea KM, Stevenson AE, SI P, . Massachusetts Department of Public Health Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010, 29:289-293. Massachusetts Department of Public Health.
12. Hsieh YC, Lin PY, Chiu CH, Huang YC, Chang KY, Liao CH, Chiu NC, Chuang YC, Chen PY, Chang SC, Liu JW, Yen MY, Wang JH, Liu CY, Lin TY. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009, 27:5513-5518. 10.1016/j.vaccine.2009.06.091, 19615960.
13. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, Lee HJ. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008, 14:275-281. 10.3201/eid1402.070807, 2600206, 18258121.
14. Skoczyńska A, Sadowy E, Bojarska K, Strzelecki J, Kuch A, Gołe{ogonek}biewska A, Waśko I, Foryś M, van der Linden M, Hryniewicz W, . Participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet) The current status of invasive pneumococcal disease in Poland. Vaccine 2011, 29:2199-2205. 10.1016/j.vaccine.2010.09.100, 20943207, Participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet).
15. Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010, 125:429-436. 10.1542/peds.2008-1702, 20176669.
16. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005, 5:83-93.
17. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines 2009, 8:977-986. 10.1586/erv.09.68, 19627181.
18. D'Ancona F, Salmaso S, Barale A, Boccia D, Lopalco PL, Rizzo C, Monaco M, Massari M, Demicheli V, Pantosti A, . Italian PNC-Euro working group Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 2005, 23:2494-2500. 10.1016/j.vaccine.2004.10.037, 15752836, Italian PNC-Euro working group.
19. Tarallo L, Tancredi F, Schito G, Marchese A, Bella A, . Italian Pneumonet Group (Società Italiana Pediatria and Associazione Italiana Studio Antimicrobici e Resistenze) Active surveillance of Streptococcus pneumoniae bacteremia in Italian children. Vaccine 2006, 24:6938-6943. 10.1016/j.vaccine.2006.05.012, 16901591, Italian Pneumonet Group (Società Italiana Pediatria and Associazione Italiana Studio Antimicrobici e Resistenze).
20. Tardivo S, Poli A, Zerman T, D'Elia R, Chiamenti G, Torri E, Bonetti A, Pedevilla E, Pancheri P, Lubrano P, Savastano R, Meneghelli G, Romano G. Invasive pneumococcal infections in infants up to three years of age: results of a longitudinal surveillance in North-East Italy. Ann Ig 2009, 21:619-628.
21. Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, Marensi L, Giacchino R, Timitilli A, Carloni R, Azzari C, Icardi G, . Collaborative Group for Pneumococcal Vaccination in Liguria Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009, 27:3459-3462. 10.1016/j.vaccine.2009.01.052, 19200823, Collaborative Group for Pneumococcal Vaccination in Liguria.
22. Baraff LJ, Bass JW, Fleisher GR, Klein JO, McCracken GH, Powell KR, Schriger DL. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med 1993, 22:1198-2210. 10.1016/S0196-0644(05)80991-6, 8517575.
23. Centers for Disease Control and Prevention Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997, 46:1-55. Centers for Disease Control and Prevention.
24. World Health Organization International Classification of Diseases, 9th Revision 1980, World Health Organization, Geneva, Switzerland, World Health Organization.
25. Centers for Disease Control and Prevention Manual for the surveillance of vaccine-preventable diseases. Chapter 11: Pneumococcal 2008, Centers for Disease Control and Prevention, Atlanta, GA, 4, http://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.htm (accessed October 29, 2011)., Centers for Disease Control and Prevention.
26. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement; M100-S19 2009, Clinical and Laboratory Standards Institute, Wayne, Clinical and Laboratory Standards Institute.
27. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010, 14:e197-e209.
28. Centers for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Centers for Disease Control and Prevention.
29. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect Dis 2010, 10:90. 10.1186/1471-2334-10-90, 2867993, 20377886.
30. De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 2009, 14:pii: 19159.
31. Istituto Superiore di Sanità Dati di sorveglianza delle malattie batteriche invasive -aggiornati al 04 aprile 2011 [in Italian] 2010, Istituto Superiore di Sanità, Rome, Italy, http://www.simi.iss.it/dati.htm (accessed October 29, 2011)., Istituto Superiore di Sanità.
32. Grijalva CG, Pelton SI. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr 2011, 23:98-104. 10.1097/MOP.0b013e328341d1f5, 3357900, 21191300.
33. Aristegui J, Bernaola E, Pocheville I, García C, Arranz L, Durán G, Pérez L, Bastida M, Canduela C, Herranz Aguirre M, Garrote E, Fletcher MA, Pérez C. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 2007, 26:303-310. 10.1007/s10096-007-0294-4, 17457623.
34. Nuorti JP, Whitney CG. Centers for Disease Control and Prevention: Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(1).
35. Overweg K, Sluijter M, Srodzinski M, de Groot R, Hermans PW. Immune-protective antibodies against capsular polysaccharides do not affect natural competence of Streptococcus pneumoniae: implications for current conjugate vaccination strategies?. FEMS Immunol Med Microbiol 2000, 29:183-185. 10.1111/j.1574-695X.2000.tb01521.x, 11064264.
36. Brandao AP, de Oliveira TC, de Cunto Brandileone MC, Goncalves JE, Yara TI, Simonsen V. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil. Vaccine 2004, 23:762-768. 10.1016/j.vaccine.2004.07.024, 15542200.
37. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO, . U.S. Pediatric Multicenter Pneumococcal Surveillance Group Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J 2006, 25:301-305. 10.1097/01.inf.0000207484.52850.38, 16567980, U.S. Pediatric Multicenter Pneumococcal Surveillance Group.